Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
Foghorn Therapeutics, a clinical-stage biotech firm focused on novel gene expression therapies for oncology, will participate in three prominent investor conferences in May 2026. Leadership will present the company's innovative Gene Traffic Control platform and pipeline at events including H.C. Wainwright Bioconnect, Stifel Virtual Targeted Oncolog…